Int J Med Sci 2020; 17(12):1763-1772. doi:10.7150/ijms.48162
FLAD1 is up-regulated in Gastric Cancer and is a potential prediction of prognosis
1. Breast Cancer Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510000, P.R. China.
2. Department of Pathology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou510000, P. R. China.
3. Department of Urologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, 400030, P.R. China.
4. Joint Surgery/Orthopedic Trauma Department, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, P. R. China.
5. General Surgery Department, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510000, P.R. China.
*These authors contributed equally to this work.
Hu P, Pan Y, Wang C, Zhang W, Huang H, Wang J, Zhang N. FLAD1 is up-regulated in Gastric Cancer and is a potential prediction of prognosis. Int J Med Sci 2020; 17(12):1763-1772. doi:10.7150/ijms.48162. Available from http://www.medsci.org/v17p1763.htm
Background: Gastric cancer (GC) is a common malignancy throughout the world. Biomarkers for prognosis and risk evaluation of GC are rapidly discovered. We investigated the prognostic role of FLAD1, an important protein-coding gene that affects cell cycle and survival.
Methods: The expression of FLAD1 at mRNA levels in GC tumor tissues and normal tissues was mined and analyzed in Oncomine database and verified in 10 pairs of GS tissues and their adjacent normal tissues in our center by RT qPCR. The FLAD1 protein expression were detected in 106 paraffin-embedded GC tissues by immunohistochemistry (IHC). Statistical analyses were applied to evaluate the clinical significance of FLAD1. The prognostic value of FLAD1 mRNA expression was also analyzed using the Kaplan-Meier plotter (
Results: Statistics obtained from online database suggested FLAD1 mRNA was overexpressed in GC tissues. The results were further validated in 10 pairs of GS tissues and adjacent normal tissues in our center (p=0.021). IHC and survival analysis of GC samples from 106 patients showed FLAD1 was overexpressed in 63/106 (59.4%) patients and was associated to higher TNM stage (p=0.026). Multivariate analysis revealed FLAD1 was an independent prognostic factor for GC (p < 0.001). Furthermore, FLAD1 mRNA was associated to unfavorable overall survival (OS), first progression (FP), and post-progression survival (PPS) of GC (p<0.001).
Conclusion: FLAD1 in GC is overexpressed at both mRNA and protein level and could be a potential biomarker for GC prognosis.
Keywords: FLAD1, biomarker, overexpression, gastric cancer, prognosis